Enrichment factors for clinical trials in mild-to-moderate Alzheimer's disease

INTRODUCTION: Heterogeneity of outcomes in Alzheimer's disease (AD) clinical trials necessitates large sample sizes and contributes to study failures. This analysis determined whether mild-to-moderate AD populations could be enriched for cognitive decline based on apolipoprotein (APOE) ε4 genot...

Descripción completa

Detalles Bibliográficos
Autores principales: Ballard, Clive, Atri, Alireza, Boneva, Neli, Cummings, Jeffrey L., Frölich, Lutz, Molinuevo, José Luis, Tariot, Pierre N., Raket, Lars Lau
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Featured Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527908/
https://www.ncbi.nlm.nih.gov/pubmed/31193334
http://dx.doi.org/10.1016/j.trci.2019.04.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527908/
https://www.ncbi.nlm.nih.gov/pubmed/31193334
http://dx.doi.org/10.1016/j.trci.2019.04.001

Ejemplares similares